Voices
Allison Fitzgerald
Allison Fitzgerald/LinkedIn

Allison Fitzgerald: Learning About the First Approved TCR T-Cell Therapy

Allison Fitzgerald, Hematology/Oncology Clinical Fellow at Dana-Farber Cancer Institute, shared a post on X:

“Today I learned about afami-cel, the first TCR T cell therapy approved.

It’s used to treat metastatic synovial sarcoma. It targets HLA-A*02 expressing MAGE-A4 on cancer cells. It is essentially the first engineered cell therapy approved for solid tumors.”

More posts about Solid Tumors.

Afami-cel Allison Fitzgerald cancer OncoDaily Oncology solid tumors TCR-T cell therapy